iRadimed Corporation (NASDAQ:IRMD – Get Free Report) has earned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $120.00.
Several equities analysts recently weighed in on IRMD shares. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Needham & Company LLC initiated coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating on the stock.
Get Our Latest Stock Report on IRMD
Insider Activity
Institutional Investors Weigh In On iRadimed
Several large investors have recently bought and sold shares of the business. Aquatic Capital Management LLC raised its position in iRadimed by 228.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 7,267 shares of the medical equipment provider’s stock valued at $627,000 after purchasing an additional 5,052 shares in the last quarter. Aristides Capital LLC grew its position in shares of iRadimed by 13.8% during the 3rd quarter. Aristides Capital LLC now owns 36,945 shares of the medical equipment provider’s stock worth $3,185,000 after buying an additional 4,482 shares in the last quarter. Entropy Technologies LP grew its position in shares of iRadimed by 310.6% during the 3rd quarter. Entropy Technologies LP now owns 10,265 shares of the medical equipment provider’s stock worth $885,000 after buying an additional 7,765 shares in the last quarter. Virtus Advisers LLC increased its stake in shares of iRadimed by 16.7% during the third quarter. Virtus Advisers LLC now owns 2,189 shares of the medical equipment provider’s stock valued at $189,000 after buying an additional 314 shares during the period. Finally, R Squared Ltd purchased a new position in shares of iRadimed during the third quarter valued at $239,000. Institutional investors own 92.34% of the company’s stock.
iRadimed Price Performance
Shares of IRMD opened at $83.45 on Wednesday. iRadimed has a 1 year low of $76.35 and a 1 year high of $107.90. The company has a 50 day simple moving average of $85.30 and a two-hundred day simple moving average of $91.72. The firm has a market cap of $1.07 billion, a P/E ratio of 44.63 and a beta of 0.91.
iRadimed (NASDAQ:IRMD – Get Free Report) last released its earnings results on Friday, October 30th. The medical equipment provider reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. iRadimed had a net margin of 26.85% and a return on equity of 23.90%. The firm had revenue of $24.20 million for the quarter, compared to the consensus estimate of $23.47 million. On average, sell-side analysts anticipate that iRadimed will post 1.92 earnings per share for the current year.
iRadimed Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, November 13th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, November 13th. iRadimed’s payout ratio is 42.78%.
iRadimed Company Profile
iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. Its products include MRI-compatible patient monitoring systems and intravenous infusion pumps, along with related accessories. The company’s monitoring systems help clinicians track patients during MRI procedures, while its infusion pumps deliver fluids and medications in the MRI suite. iRadimed’s equipment is designed to operate in the presence of MRI magnets, where conventional medical devices may not be suitable.
Featured Articles
- Five stocks we like better than iRadimed
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
